Neratinib Tablets

FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer. On July 17, 2017, the U.S. Food and Drug Administration approved neratinib (NERLYNX, Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early stage HER2- verexpressed / amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.